Coversyl Arginine 5mg orodispersible tablets
- Name:
Coversyl Arginine 5mg orodispersible tablets
- Company:
Servier Laboratories Ireland Ltd
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may be renewed (B)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 20/03/19
(Click to Download)Click on this link to Download PDF directly
Servier Laboratories Ireland Ltd
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 20 March 2019 PIL
Reasons for updating
- Change to section 4 - possible side effects
Updated on 20 March 2019
Reasons for updating
- Change to section 4.8 - Undesirable effects
Updated on 29 May 2018
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 29 May 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
Updated on 30 May 2017 SPC
Reasons for updating
- Change to section 6.3 - Shelf life
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 30 May 2017
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 8 November 2016 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
- 4.4 Special warnings and precautions for use
Hypersensitivity/Angioedema: Addition of concomitant use of mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus)
- 4.5 Interaction with other medicinal products and other forms of interaction
Concomitant use not recommended (see section 4.4):Addition of: Racecadotril and mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus)
- 4.8 Undesirable effects
Tabulated list of adverse reactions
Skin and Subcutaneous Tissue Disorders: Addition of: Psoriasis aggravation
Updated on 4 November 2016 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 4 - possible side effects
Updated on 4 November 2016 PIL
Reasons for updating
- New PIL for new product
Updated on 18 August 2016 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 17 August 2016 PIL
Reasons for updating
- New PIL for new product